Stephen V Liu: Update from the Phase 2 PHAROS Study
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Update from the Phase 2 PHAROS Study of Encorafenib and Binimetinib in BRAF V600E NSCLC JTO & JTO CRR.
As 1L therapy, RR 75%, DOR 40m, PFS 30m, 3y OS rate 53%. In previously treated, RR 46%, DOR 16.7m, PFS 9.3m, OS 22.7m, 3y OS 29%.”
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report.
Authors: Gregory J. Riely, Myung-Ju Ahn, Jeffrey M. Clarke, Ibiayi Dagogo-Jack, Raymond Esper, Enriqueta Felip, Francesco Gelsomino, Jonathan W. Goldman, Maen Hussein, Melissa Johnson, Kristen A. Marrone, Daniel Morgensztern, Ernest Nadal, Marcelo V. Negrao, Michael Offin, Mariano Provencio, Suresh S. Ramalingam, Logan Roof, Rachel E. Sanborn, Egbert F. Smit, Anne Tsao, Tiziana Usari, Ann Alcasid, Keith Wilner, Svitlana Tonkovyd, Xiaosong Zhang, and Bruce E. Johnson.
You can read the full article on Journal of Thoracic Oncology.
More posts featuring Stephen V Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023